Daily CSR
Daily CSR

Daily CSR

Daily news about corporate social responsibility, ethics and sustainability
Tags (2) : AML

Mabwell Advances 6MW5311 Bispecific Antibody for AML and Blood Cancers

Mabwell Advances 6MW5311 Bispecific Antibody for AML and Blood Cancers
04/16/2026 | Companies
Mabwell (688062.SH), an innovation-focused biopharmaceutical company with an integrated value chain, has announced that the National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for its novel LILRB4/CD3 T cell engager (TCE) bispecific antibody,...
6MW5311, acute myeloid leukemia, AML, biopharmaceuticals, biotechnology, bispecific antibody, cancer research, CD3, chronic myelomonocytic leukemia, clinical trials, CMML, cytotoxicity, drug development, FDA, hematologic malignancies, immune synapse, immunotherapy, IND application, LILRB4, Mabwell, MM, multiple myeloma, NMPA, oncology, preclinical studies, stem cell transplantation, steric hindrance, T cell engager, targeted therapy, TCE technology, tumor inhibition

Revolutionizing Blood Cancer Diagnosis with Whole-Genome Sequencing

Revolutionizing Blood Cancer Diagnosis with Whole-Genome Sequencing
12/16/2024 | Companies
The Leukemia & Lymphoma Society projects that by the end of 2024, approximately 187,740 Americans will be diagnosed with blood cancer, equating to about one new case every three minutes. This statistic highlights the complexity of diagnosing and treating these conditions. Traditional diagnostic...
AML, bioinformatics, blood cancer, cancer prognosis, cancer treatment, copy number alterations, diagnostic technology, genetic testing, genomic profiling, healthcare innovation, Illumina, leukemia, lymphoma, medical research, mutational analysis, precision medicine, risk stratification, sequencing technology, structural variants, tumor analysis, whole-genome sequencing


Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com